13F HOLDINGS REPORT
Remedium Capital Partners, LLC
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0002104501-26-000004
Total Value
$170,211
Positions
6
Other Managers
0
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Spyre Therapeutics Inc | SYRE | 1,456,231 | $47,706 | 28.03% |
| 2 | Oruka Therapeutics Inc | ORKA | 1,552,414 | $47,054 | 27.64% |
| 3 | Apogee Therapeutics Inc | APGE | 583,591 | $44,050 | 25.88% |
| 4 | Jade Biosciences Inc | JBIO | 1,577,750 | $24,345 | 14.30% |
| 5 | Crescent Biopharma Inc | CBIO | 361,250 | $4,284 | 2.52% |
| 6 | Galecto Inc | 36322Q206 | 120,473 | $2,772 | 1.63% |